Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)

Cervical Cancer Screening Clinical Trial

Official title:

Bio Colposcopy System CIP: Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03750214
• Other study ID #: CLP - 430
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 2020
• Est. completion date: December 2020

Study information

• Verified date: January 2020
• Source: BIOP Medical
• Contact: Dana Raveh Arbel
• Phone: 972528591891
• Email: dana[@]biopmedical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, prospective, non-randomized, confirmatory study to evaluate the safety and performance of the Biop Digital Colposcope and the accuracy of the image registration procedure between the Biop Digital Colposcope unit and the Biop Micro Colposcope probe unit.

Description:

This is a multi-center, prospective, non-randomized, confirmatory study to evaluate the safety and performance of the Biop Digital Colposcope and the accuracy of the image registration procedure between the Biop Digital Colposcope unit and the Biop Micro Colposcope probe unit.

The Biop Digital Colposcope is intended for magnified viewing of the tissues of the vagina, cervix and external genitalia in order to assist doctors in diagnosing abnormalities such as lesions or cancer, and selecting areas for biopsy. The images from the digital colposcope are to be viewed on a color display. The digital colposcope is intended for use in hospitals, clinics, and doctor's offices.

The Biop Micro Colposcope probe unit is an imaging tool intended to be placed in the vagina for acquisition of images of the cervix. It is intended as an adjunct to the Biop Digital Colposcope. It should NOT be used as a substitute for a thorough colposcopic evaluation. The Biop Micro Colposcope Probe unit is not intended for use on the vulva and vagina.

It is anticipated that it will take approximately 3 months to complete active enrollment. Study duration for each subject is 1-2 days, including screening, enrolment and procedure. The study will be completed when the final study subject has completed the procedure.

1. Performance - to confirm that average image registration error is less than or equal to (≤) 2mm.

2. Safety - to evaluate the safety of the Biop Digital Colposcope in women undergoing cervical colposcopy procedures.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 26
• Est. completion date: December 2020
• Est. primary completion date: November 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 22 Years to 65 Years

Eligibility

Inclusion Criteria:

• Females, ages 22 to 65 years old

• Referred for colposcopy, following abnormal cervical cytology

• Subject provides signed informed consent

Exclusion Criteria:

• Currently pregnant or nursing

• Currently menstruating

• Currently has intrauterine device (IUD)

• Diagnosed with diseases that may influence the color of the tissue, e.g., hepatitis, polycytemia vera.

• Diagnosed with pathologies that affect blood coagulation, the immune system or undergoing any treatment that interfere with coagulation or the immune system

• HIV-positive status

• Psychological instability, inappropriate attitude or motivation

• Use of any additional experimental drug or device or participation in another clinical study within the past 30 days

Related Conditions & MeSH terms

• Cervical Cancer Screening
• Uterine Cervical Neoplasms

Intervention

Device:
• Biop Colposcopy System
The procedure stages: Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera. Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope. A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure. A questionnaire completed by the user after the Biop procedure, with regards to system usage Image Registration analysis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
BIOP Medical

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory Endpoint	Subject's comfort - as measured by a questionnaire	procedure day ± 1 day
Primary	Performance	The primary performance endpoint is the image registration success. Image registration success is defined by the registration error (distance between corresponding control points following registration). Average image registration error should be less than or equal to (=) to 2mm.	procedure day ± 1 day
Primary	frequency and incidence of all Adverse Events	Safety endpoints include frequency and incidence of all Adverse Events (AE) and Serious Adverse Events (SAE) related and unrelated to the device use.	procedure day ± 1 day